{
  "id": 16215762,
  "title": "Torrent Pharma Profit Falls 9.6 Per Cent, Dr Reddy’s Slumps 36 Pc In Q2 FY27",
  "url": "https://urgent.news/2026/10/23/torrent-pharma-profit-falls-9-6-per-cent-dr-reddys-slumps-36-pc-in-q2",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-23T18:27:04.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/business/torrent-pharma-profit-falls-96-per-cent-dr-reddys-slumps-36-pc-in-q2-fy27"
  },
  "original_language": "en",
  "account": "In the second quarter of fiscal year 2027 (Q2 FY27), pharmaceutical companies Torrent Pharmaceuticals and Dr Reddy’s Laboratories both experienced drops in net profit. Torrent Pharmaceuticals saw a 9.6% year-over-year decrease in consolidated net profit to Rs 534 crore, while Dr Reddy’s Laboratories reported a more severe 36% decline, reducing its net profit to Rs 913.4 crore. Despite these declines, both companies demonstrated resilience in their operational performance. Torrent Pharmaceuticals reported a significant increase in revenue from operations, which surged 50.8% to Rs 4,979 crore, up from Rs 3,302 crore the previous year. However, the company faced a sharp increase in expenses, with total expenses rising 70.9% to Rs 4,222 crore. Finance costs and depreciation and amortisation expenses were the key drivers of this increase, accounting for a substantial portion of the higher expenditure. On the other hand, Dr Reddy’s Laboratories experienced a decline in both revenue from operations and EBITDA, indicating a weakening operating performance. Despite the decline in net profit, both companies managed to maintain positive earnings before interest, tax, depreciation, and amortisation (EBITDA) figures. Torrent Pharmaceuticals reported a 53.8% year-over-year increase in EBITDA to Rs 1,666 crore, while Dr Reddy’s Laboratories saw a 24.2% drop in EBITDA to Rs 1,783 crore.",
  "summary": "Mumbai, October 23, 2026: Pharmaceutical majors Torrent Pharmaceuticals and Dr Reddy’s Laboratories on Friday reported declines in net profit for the quarter ended September 2026 (Q2 FY27), as higher expenses and margin pressures weighed on earnings despite resilient operational performance. Ahmedabad-headquartered Torrent Pharmaceuticals posted a 9.6 per cent year-on-year decline in consolidated…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}